APAC Hemostats Market

September 2017 | 150 pages | ID: ABD0E3566B8EN
Data Bridge Market Research

Abstracts

In this report, APAC hemostats market is expected to reach USD 595.1 million by 2024, from USD 327.6 million in 2016 growing at a CAGR of 7.8% in the forecast period 2017 to 2024.

Based on geography, the APAC hemostats market is segmented into 11 geographical regions, such as,

• Japan,
• China,
• South Korea,
• India,
• Australia,
• Singapore,
• Thailand,
• Malaysia,
• Indonesia,
• Philippines and
• Rest of APAC.

APAC hemostats market competition by top players including

Ethicon US LLC (U.S.) is dominating the hemostats market followed by Pfizer and C.R. Bard Inc., along with others such as

• Baxter,
• Vascular Solutions, Inc.,
• B.Braun Melsungen,
• 3-D Matrix, Ltd.,
• Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company),
• Anika Therapeutics, Inc.,
• Arch Therapeutics Inc.,
• Biom’Up SAS,
• CryoLife, Inc.,
• Gamma Therapeutics, Inc.,
• Hemostasis, LLC,
• MedTrade Products Limited, I
• ntegra LifeSciences Corporation,
• Medline Industries, Inc.,
• HEMOTEC MEDICAL GMBH,
• Stryker,
• CSL Behring,
• Mallinckrodt,
• Equimedical, B.V.

The APAC hemostats market is segmented on the basis of type, application, distribution channel, and end user.

The APAC hemostats market is segmented into 5 major types, namely thrombin based hemostats, combination agents, oxidized regenerated cellulose based haemostats, gelatin based haemostats and collagen based haemostats.

On the basis of application, the market is segmented into surgery and wound closure.

On the basis of end users, the market is classified into hospitals, community healthcare, ambulatory centres and clinics.

Contents

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF ASIA PACIFIC HEMOSTATS MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCE
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS
  3.1.1. CHRONIC CONDITIONS AND AGING POPULATION LEADING TO INCREASE IN NUMBER OF SURGICAL PROCEDURES
  3.1.2. TECHNOLOGICAL ADVANCEMENTS
  3.1.3. INCREASING NUMBER OF MINIMALLY INVASIVE SURGERIES
  3.1.4. IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING HEALTHCARE SPENDING
3.2. RESTRAINTS
  3.2.1. RELUCTANCE OF SURGEONS TOWARDS NEW PRODUCTS
  3.2.2. WEAK REIMBURSEMENT
3.3. OPPORTUNITIES
  3.3.1. UNMET MEDICAL NEEDS
  3.3.2. EMERGING MARKET
3.4. CHALLENGES
  3.4.1. DEVELOPMENT OF SUBSTITUTE PRODUCTS
  3.4.2. LIMITATIONS OF HEMOSTATIC AGENTS IN ACHIEVING HEMOSTASIS

4. PREMIUM INSIGHTS

5. REGULATORY

5.1. OVERVIEW
5.2. REGULATORY PROCEDURE

6. REIMBURSEMENT

6.1. OVERVIEW
6.2. REIMBURSEMENT SCENARIO

7. EXECUTIVE SUMMARY

8. ASIA PACIFIC HEMOSTATS MARKET, BY TYPE

8.1. OVERVIEW
8.2. THROMBIN BASED HEMOSTATS
8.3. COMBINATION AGENT HEMOSTATS
8.4. OXIDIZED REGENERATED CELLULOSE BASED HEMOSTATS
8.5. GELATIN BASED HEMOSTATS
8.6. COLLAGEN BASED HEMOSTATS

9. ASIA PACIFIC HEMOSTATS MARKET,BY APPLICATION

9.1. OVERVIEW
9.2. ASIA PACIFIC HEMOSTATS MARKET, BY APPLICATION
9.3. WOUND CLOSURE
9.4. SURGICAL HEMOSTATS

10. ASIA PACIFIC HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL

10.1. OVERVIEW
  10.1.1. DIRECT TENDERS
  10.1.2. RETAIL

11. ASIA PACIFIC HEMOSTATS MARKET, BY END USER

11.1. OVERVIEW
11.2. HOSPITALS
11.3. AMBULATORY CENTERS
11.4. COMMUNITY HEALTHCARE
11.5. CLINICS

12. ASIA PACIFIC HEMOSTATS MARKET, BY GEOGRAPHY

12.1. OVERVIEW
12.2. ASIA-PACIFIC (APAC)
  12.2.1. JAPAN
  12.2.2. CHINA
  12.2.3. SOUTH KOREA
  12.2.4. INDIA
  12.2.5. AUSTRALIA
  12.2.6. SINGAPORE
  12.2.7. THAILAND
  12.2.8. MALAYSIA
  12.2.9. INDONESIA
  12.2.10. PHILIPPINES
  12.2.11. REST OF APAC

13. ASIA PACIFIC HEMOSTATS MARKET, COMPANY LANDSCAPE

13.1. COMPANY SHARE ANALYSIS: ASIA PACIFIC
13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3. COMPANY SHARE ANALYSIS: EUROPE
13.4. COMPANY SHARE ANALYSIS: APAC

14. COMPANY PROFILES

14.1. ETHICON US, LLC (SUBSIDIARY OF JOHNSON &
JOHNSON SERVICES, INC)
  14.1.1. COMPANY OVERVIEW
  14.1.2. REVENUE ANALYSIS
  14.1.3. PRODUCT PORTFOLIO
  14.1.4. RECENT DEVELOPMENTS
14.2. PFIZER
  14.2.1. COMPANY OVERVIEW
  14.2.2. REVENUE ANALYSIS
  14.2.3. PRODUCT PORTFOLIO
  14.2.4. RECENT DEVELOPMENTS
14.3. C.R BARD
  14.3.1. COMPANY OVERVIEW
  14.3.2. REVENUE ANALYSIS
  14.3.3. PRODUCT PORTFOLIO
  14.3.4. RECENT DEVELOPMENTS
14.4. BAXTER
  14.4.1. COMPANY OVERVIEW
  14.4.2. REVENUE ANALYSIS
  14.4.3. PRODUCT PORTFOLIO
  14.4.4. RECENT DEVELOPMENTS
14.5. VASCULAR SOLUTIONS, INC
(ACQUIRED BY TELEFLEX INCORPORATED)
  14.5.1. COMPANY OVERVIEW
  14.5.2. REVENUE ANALYSIS
  14.5.3. PRODUCT PORTFOLIO
  14.5.4. RECENT DEVELOPMENTS
14.6. B.BRAUN MELSUNGEN AG
  14.6.1. COMPANY OVERVIEW
  14.6.2. REVENUE ANALYSIS
  14.6.3. PRODUCT PORTFOLIO
  14.6.4. RECENT DEVELOPMENTS
14.7. 3-D MATRIX LTD
  14.7.1. COMPANY OVERVIEW
  14.7.2. REVENUE ANALYSIS
  14.7.3. PRODUCT PORTFOLIO
  14.7.4. RECENT DEVELOPMENTS
14.8. RESORBA MEDICAL GMBH
  14.8.1. COMPANY OVERVIEW
  14.8.2. REVENUE ANALYSIS
  14.8.3. PRODUCT PORTFOLIO
  14.8.4. RECENT DEVELOPMENTS
14.9. ANIKA THERAPEUTICS, INC.
  14.9.1. COMPANY OVERVIEW
  14.9.2. REVENUE ANALYSIS
  14.9.3. PRODUCT PORTFOLIO
  14.9.4. RECENT DEVELOPMENTS
14.10. BIOM’UP
  14.10.1. COMPANY OVERVIEW
  14.10.2. REVENUE ANALYSIS
  14.10.3. PRODUCT PORTFOLIO
  14.10.4. RECENT DEVELOPMENTS
14.11. CRYOLIFE, INC.
  14.11.1. COMPANY OVERVIEW
  14.11.2. REVENUE ANALYSIS
  14.11.3. PRODUCT PORTFOLIO
  14.11.4. RECENT DEVELOPMENTS
14.12. EQUIMEDICAL
  14.12.1. COMPANY OVERVIEW
  14.12.2. REVENUE ANALYSIS
  14.12.3. PRODUCT PORTFOLIO
  14.12.4. RECENT DEVELOPMENTS
14.13. HEMOSTASIS, LLC
  14.13.1. COMPANY OVERVIEW
  14.13.2. REVENUE ANALYSIS
  14.13.3. PRODUCT PORTFOLIO
  14.13.4. RECENT DEVELOPMENTS
14.14. MEDTRADE PRODUCTS LIMITED
  14.14.1. COMPANY OVERVIEW
  14.14.2. REVENUE ANALYSIS
  14.14.3. PRODUCT PORTFOLIO
  14.14.4. RECENT DEVELOPMENTS
14.15. STRYKER
  14.15.1. COMPANY OVERVIEW
  14.15.2. REVENUE ANALYSIS
  14.15.3. PRODUCT PORTFOLIO
  14.15.4. RECENT DEVELOPMENTS
14.16. ARCH THERAPEUTICS, INC.
  14.16.1. COMPANY OVERVIEW
  14.16.2. REVENUE ANALYSIS
  14.16.3. PRODUCT PORTFOLIO
  14.16.4. RECENT DEVELOPMENTS
14.17. INTEGRA LIFESCIENCES CORPORATION
  14.17.1. COMPANY OVERVIEW
  14.17.2. REVENUE ANALYSIS
  14.17.3. PRODUCT PORTFOLIO
  14.17.4. RECENT DEVELOPMENTS
14.18. ALTAYLAR MEDICAL
  14.18.1. COMPANY OVERVIEW
  14.18.2. REVENUE ANALYSIS
  14.18.3. PRODUCT PORTFOLIO
  14.18.4. RECENT DEVELOPMENTS
14.19. BIOCER ENTWICKLUNGS-GMBH
  14.19.1. COMPANY OVERVIEW
  14.19.2. REVENUE ANALYSIS
  14.19.3. PRODUCT PORTFOLIO
  14.19.4. RECENT DEVELOPMENTS
14.20. SMI (STARCH MEDICAL)
  14.20.1. COMPANY OVERVIEW
  14.20.2. REVENUE ANALYSIS
  14.20.3. PRODUCT PORTFOLIO
  14.20.4. RECENT DEVELOPMENTS

15. RELATED REPORTS

TABLE LIST

TABLE 1 APAC HEMOSTATS S MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)
TABLE 2 APAC HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 3 APAC HEMOSTATS MARKET, BY APPLICATION,2015 – 2024 (USD MILLION)
TABLE 4 APAC HEMOSTATS MARKET, BY END USER,2015 – 2024 (USD MILLION)
TABLE 5 APAC HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 6 JAPAN HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 7 JAPAN HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 8 JAPAN HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 9 JAPAN HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 10 CHINA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 11 CHINA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 12 CHINA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 13 CHINA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 14 SOUTH KOREAHEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
TABLE 15 SOUTH KOREA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 16 SOUTH KOREA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 17 SOUTH KOREA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 18 INDIA HEMOSTATS MARKET, BY PRODUCT TYPE,2015 – 2024(USD MILLION)
TABLE 19 INDIA HEMOSTATS MARKET, BY APPLICATION,2015 – 2024 (USD MILLION)
TABLE 20 INDIA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 21 INDIA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 22 AUSTRALIA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 23 AUSTRALIA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 24 AUSTRALIA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 25 AUSTRALIA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 26 SINGAPORE HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 27 SINGAPORE HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 28 SINGAPORE HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 29 SINGAPORE HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 30 THAILAND HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 31 THAILAND HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 32 THAILAND HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 33 THAILAND HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 34 MALAYSIA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 35 MALAYSIA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 36 MALAYSIA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 37 MALAYSIA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 38 INDONESIA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 39 INDONESIA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 40 INDONESIA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 41 INDONESIA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 42 PHILIPPINES HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 43 PHILIPPINES HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 44 PHILIPPINES HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 45 PHILIPPINES HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 46 REST OF APACHEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)

Figures

FIGURES LIST

FIGURE 1 ASIA PACIFIC IS THE HIGHEST GROWING AND MOST PROFITABLE REVENUE POCKETS FOR HEMOSTATS MANUFACTURERS
IN THE FORECAST PERIOD TO 2024
FIGURE 2 APAC HEMOSTATS MARKET SNAPSHOT (2017)
FIGURE 3 APAC HEMOSTATS MARKET: BY GEOGRAPHY (2016)
FIGURE 4 APAC HEMOSTATS MARKET:BY COUNTRY (2017)
FIGURE 5 APAC HEMOSTATS MARKET BY COUNTRY (2016 & 2024)
FIGURE 6 APAC HEMOSTATS MARKET BY PRODUCT TYPE (2017 & 2024)
FIGURE 7 APAC HEMOSTATS MARKET: COMPANY SHARE 2016 (%)

COMPNIES PROFILES

Anika Therapeutics, Inc., Arch Therapeutics Inc., Biom’Up SAS, CryoLife, Inc., Gamma Therapeutics, Inc., Hemostasis, LLC, MedTrade Products Limited, I ntegra LifeSciences Corporation, Medline Industries, Inc., HEMOTEC MEDICAL GMBH, Stryker, CSL Behring, Mallinckrodt, Equimedical, B.V.